Summary
- The Competition Commission of India (CCI) has dismissed allegations of excessive pricing against a private super-specialty hospital.
- The CCI determined that higher charges for tests, medicines, and consumables did not constitute abuse of dominance.
- The Commission found a lack of sufficient evidence to prove that the pricing was both excessive and unfair.
- This ruling underscores the challenges in proving pricing abuses in the healthcare sector.
Join the discussion ā sign up to comment, upvote, and save articles.